Eisai company profile
Company profile
Eisai has 10,543 employees and is headquartered in Tokyo, Japan.
Eisai is known mainly through Lenvima, LEQEMBI and Dayvigo, the products of a Japanese pharmaceutical company that researches, develops, manufactures and sells drugs in Japan and abroad. Its focus lies in neurology and oncology, and its range includes prescription drugs and over-the-counter medicines. LEQEMBI is a humanized IgG1 monoclonal antibody against amyloid-beta protofibrils, Lenvima is a multi-kinase inhibitor involved in tumor angiogenesis, and Dayvigo is a novel small molecule compound. Sales extend to Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia and the Global South.
In the fiscal year ended March 2026, Eisai posted revenue of 825.4 billion yen, up 4.6% from the previous year, and net income of 38.6 billion yen. The company employed 10,543 people and is headquartered in Tokyo, where it was incorporated in 1941. It was formerly known as Nihon Eisai and took its current name in 1955.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Japan
- Headquarters
- 4-6-10 Koishikawa, 112-8088, Tokyo
- Employees
- 10,543
- Chief executive
- Haruo Naito
- Founded
- 1941
- Fiscal year
- April - March
- Listing
- 4523 · TSE
- Indices
- Nikkei 225
- Currency
- JPY
- ISIN
- JP3160400002
- Website
- eisai.co.jp
Eisai and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Eisai4523 | Japan | $9.14B | 10,543 | 6.7% | 33.3 |
| Kyowa Kirin4151 | Japan | $8.46B | 5,161 | 21.8% | 16.6 |
| CiplaCIPLA | India | $11.93B | 31,369 | 13.0% | 38.8 |
| Zhejiang NHU002001 | China | $12.3B | 11,508 | 33.8% | 10.9 |
| Zydus LifesciencesZYDUSLIFE | India | $12.59B | 29,980 | 17.2% | 28.4 |
| Laurus LabsLAURUSLABS | India | $13.9B | 7,059 | 24.1% | 97.8 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
